Late-Onset Retinal Degeneration Overview

Save information for later
Sign Up

Learn About Late-Onset Retinal Degeneration

What is the definition of Late-Onset Retinal Degeneration?
Late-onset retinal degeneration is an inherited retinal dystrophy characterized by delayed dark adaptation and nyctalopia and drusen deposits presenting in adulthood, followed by cone and rod degeneration that presents in the sixth decade of life, which leads to central vision loss. Anterior segment features such as peripupillary iris transillumination defects and abnormally long anterior zonular insertions are also observed. Choroidal neovascularization and glaucoma may occur in the late stages of the disease.
What are the alternative names for Late-Onset Retinal Degeneration?
  • Late-onset retinal degeneration
  • Autosomal dominant late-onset retinal degeneration
  • LORD
  • Pigmentary retinopathy
  • Retinal degeneration, late-onset, autosomal dominant
Who are the top Late-Onset Retinal Degeneration Local Doctors?
Distinguished in Late-Onset Retinal Degeneration
Dr. Jennifer R. Olbum
Ophthalmology
Distinguished in Late-Onset Retinal Degeneration
Dr. Jennifer R. Olbum
Ophthalmology

Sanford Medical Center Fargo

2400 32nd Ave S, 
Fargo, ND 
 (3.4 mi)
701-234-2000
Languages Spoken:
English, French
See accepted insurances
Accepting New Patients

Jennifer Olbum is an Ophthalmologist in Fargo, North Dakota. Dr. Olbum and is rated as a Distinguished provider by MediFind in the treatment of Late-Onset Retinal Degeneration. Her top areas of expertise are Diabetic Retinopathy, Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, and Retinal Artery Occlusion. Dr. Olbum is currently accepting new patients.

Advanced in Late-Onset Retinal Degeneration
Dr. Mariaha J. Cobb
Ophthalmology
Advanced in Late-Onset Retinal Degeneration
Dr. Mariaha J. Cobb
Ophthalmology

Innovis Health LLC

1702 University Dr S, 
Fargo, ND 
 (1.7 mi)
701-364-8900
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Mariaha Cobb is an Ophthalmologist in Fargo, North Dakota. Dr. Cobb and is rated as an Advanced provider by MediFind in the treatment of Late-Onset Retinal Degeneration. Her top areas of expertise are Sjogren Syndrome, Cataract, Late-Onset Retinal Degeneration, and Age-Related Macular Degeneration (ARMD). Dr. Cobb is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Advanced in Late-Onset Retinal Degeneration
Dr. Steven K. Anderson
Ophthalmology
Advanced in Late-Onset Retinal Degeneration
Dr. Steven K. Anderson
Ophthalmology

Sanford Medical Center Fargo

1717 University Dr S, 
Fargo, ND 
 (1.7 mi)
701-461-5100
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Steven Anderson is an Ophthalmologist in Fargo, North Dakota. Dr. Anderson and is rated as an Advanced provider by MediFind in the treatment of Late-Onset Retinal Degeneration. His top areas of expertise are Glaucoma, Cataract, Blocked Tear Duct, and Eyelid Bump. Dr. Anderson is currently accepting new patients.

View All Doctors
What are the latest Late-Onset Retinal Degeneration Clinical Trials?
A Phase I, Multipart, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7497372 Following Intravitreal Administration in Participants With Diabetic Macular Edema (Part 1 Non-Randomized, Open-Label, Multiple Ascending Dose; Part 2 Randomized, Double-Masked)
A Phase I, Multipart, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7497372 Following Intravitreal Administration in Participants With Diabetic Macular Edema (Part 1 Non-Randomized, Open-Label, Multiple Ascending Dose; Part 2 Randomized, Double-Masked)
Enrollment Status: Recruiting
Publish Date: February 26, 2025
Intervention Type: Drug
Study Phase: Phase 1

Summary: This study will assess the safety and tolerability of RO7497372 in participants with DME. The study consists of 2 parts. Part 1 will test multiple-ascending doses of RO7497372 after unilateral intravitreal (IVT) administration in participants with DME. The main purpose of Part 1 is to provide data for RO7497372 safety and tolerability, as well as to characterize the ocular and systemic pharmacokin...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A 2-year Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects with Wet AMD
A 2-year Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects with Wet AMD
Enrollment Status: Recruiting
Publish Date: February 25, 2025
Intervention Type: Drug
Study Phase: Phase 3

Summary: This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center